PPARG and acute myeloid leukemia: From the translational perspective, PPARG inhibition might serve as a new treatment for AML, given that mTORC1 inhibitors are unable to completely eradicate AML (Bissler et al, 2008, 2013) and were shown to result in significant side effects (Trelinska et al, 2015).